DMD
Dystrophin
As of the edition of 20 October 2026, DMD (dystrophin, UniProt P11532) has 6 drugs tested at it and 5 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P11532
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 6
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Nervous system
- Registered trials of its drugs
- 36
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Stopped | 2 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Eteplirsen | Marketed | Phase 3 | none listed |
| Drisapersen | Stopped | Phase 3 | none listed |
| Viltolarsen | Marketed | Phase 4 | Ends 2034 |
| Golodirsen | Marketed | Phase 4 | Ends 2026 |
| Casimersen | Marketed | Phase 3 | Ends 2030 |
| Suvodirsen | Stopped | Phase 3 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Amicus Therapeutics | Route A |
| Wave Life Sciences | Route A |
| GSK | Route A |
The other 2 companies at DMD
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at DMD, ranked, with the facts behind eachRequest access. Nothing is shown until you do.